Clinical Trials Sponsored by Jiangsu Wanbang Medicine Marketing Co., Ltd.

Total 672 results

Fudan University
Peking University People's Hospital; Jiangsu Wanbang Medicine Marketing Co....

Unknown

Safety and Efficacy of Statins for Chinese Patients With Dyslipidemia

Dyslipidemias

China
Peking University First Hospital
Jiangsu Wanbang Pharmaceutical Marketing Co.,Ltd.

Unknown

Efficacy of Dun Ye Guan Xin Ning Tablet in Patients With Stable Angina Pectoris

Coronary Heart Disease

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Non-Small Cell Lung Cancer With HER2- Mutations

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Clinical Trial of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults

Gout With Hyperuricemia in Adults
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Advanced KRAS G12D Mutant Solid Tumors

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects.

Adult Patients With Chronic Primary ITP | Adult Patients With SAA Who do Not Respond Well to Immunosuppressive Therapy

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

Recurrent Ovarian Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of Remimazolam Tosilate for Sedation in Non-intubated Diagnostic and Therapeutic Procedures

Sedation in Non-intubated Diagnostic and Therapeutic Procedures

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults

Gout With Hyperuricemia in Adults
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer

Advanced Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

To Compare the Efficacy and Safety of Oral SHR 7280 Tablets With Ganirelix Acetate Injection in Infertile Female Subjects

Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-A1811 in Subjects With Gynaecologic Oncology

Gynaecological Malignancies

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Advanced Gastroenteropancreatic Neuroendocrine Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia

Immune Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects

Castration-Resistant Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.

Autoimmune Hepatitis

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer

Advanced Esophageal Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma

Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of HR091506 Tablets in Treatment of Primary Gout With Hyperuricemia in Adults

Primary Gout With Hyperuricemia in Adults
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Non-Radiographic Axial Spondyloarthritis

Non-radiographic Axial Spondyloarthritis

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of HRS7415 Tablets in Patients With Advanced Malignant Tumors

Advanced Malignant Tumor
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of HR17031 Injection With Renal Insufficiency

Improved Glycemic Control in Patients With Type 2 Diabetes
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HR011408 at Two Formulations in Healthy Subject

Diabetes in Adults
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Extension Study of Hetrombopag in Severe Aplastic Anemia

Treatment-naive Severe Aplastic Anemia

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial to Evaluate the Safety and PK Profile of HRS4800 in Healthy Subjects

Pain
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia

Immune Thrombocytopenia

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

Hepatic Impairment | Healthy Participants

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Relapsed Ovarian Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer

Pancreatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Renal Cell Carcinoma | Cervical Cancer | Endometrial Cancer | Urothelial Carcinoma | Ovarian Cancer Recurrent

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR-1701 in Metastatic or Locally Advanced Solid Tumors

Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma

Sarcoma

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Assessment of Gastric Emptying by SHR20004 in Healthy Subjects

Type 2 Diabetes Mellitus

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy Subject

Diabetes

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Locally Advanced or Metastatic and Unresectable HCC

United States, Spain, China, Taiwan, Belgium, Korea, Republic of, Italy, Hong Kong, Russian Federation, Ukraine, Turkey, Poland, Germany
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

Esophageal Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

Gastric Cancer | GastroEsophageal Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia

Severe Aplastic Anemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability

Graft-versus-host Disease

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype

Asthma With Eosinophilic Phenotype

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

Advanced Malignancies

Australia, China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer

Hormone Sensitive Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of Irinotecan Liposome in Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China

Clinical Trials Sponsored by Jiangsu Wanbang Medicine Marketing Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations